Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
Martín, Miguel ; Carrasco, Eva ; Rodríguez-Lescure, Álvaro ; Andrés, Raquel (Universidad de Zaragoza) ; Servitja, Sonia ; Antón, Antonio (Universidad de Zaragoza) ; Ruiz-Borrego, Manuel ; Bermejo, Begoña ; Guerrero, Ángel ; Ramos, Manuel ; Santaballa, Ana ; Muñoz, Montserrat ; Cruz, Josefina ; Lopez-Tarruella, Sara ; Chacón, Jose I. ; Álvarez, Isabel ; Martínez, Purificación ; Miralles, Juan J. ; Polonio, Óscar ; Jara, Carlos ; Aguiar-Bujanda, David
Resumen: Purpose
The monarchE trial showed that the addition of abemaciclib improves efficacy in patients with high-risk early breast cancer (EBC). We analyzed the long-term outcomes of a population similar to the monarchE trial to put into context the potential benefit of abemaciclib.
Methods
HR-positive/HER2-negative EBC patients eligible for the monarchE study were selected from 3 adjuvant clinical trials and a breast cancer registry. Patients with ≥ 4 positive axillary lymph nodes (N +) or 1–3 N + with tumor size ≥ 5 cm and/or histologic grade 3 and/or Ki67 ≥ 20%, who had undergone surgery with curative intent and had received anthracyclines ± taxanes and endocrine therapy in the neoadjuvant and /or adjuvant setting were included. We performed analysis of Invasive Disease-Free Survival (iDFS), Distant Disease-Free Survival (dDFS) and Overall Survival (OS) at 5 and 10 years, as well as yearly (up to 10) of Invasive Relapse Rate (IRR), Distant Relapse Rate (DRR) and Death Rate (DR).
Results
A total of 1,617 patients were analyzed from the GEICAM-9906 (312), GEICAM-2003–10 (210), and GEICAM-2006–10 (160) trials plus 935 from El Álamo IV. With a median follow-up of 10.1 years, the 5 and 10 years iDFS rates were 75.2% and 57.0%, respectively. The dDFS and OS rates at 5 years were 77.4% and 88.8% and the respective figures at 10 years were 59.7% and 70.9%.
Conclusions
This data points out the need for new therapies for those patients. A longer follow-up of the monarchE study to see the real final benefit with abemaciclib is warranted.
Idioma: Inglés
DOI: 10.1007/s10549-023-07002-1
Año: 2023
Publicado en: BREAST CANCER RESEARCH AND TREATMENT 201, 2 (2023), 151-159
ISSN: 0167-6806
Factor impacto JCR: 3.0 (2023)
Categ. JCR: ONCOLOGY rank: 142 / 322 = 0.441 (2023) - Q2 - T2
Factor impacto CITESCORE: 6.8 - Cancer Research (Q2) - Oncology (Q2)
Factor impacto SCIMAGO: 1.267 - Oncology (Q1) - Cancer Research (Q2)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
Exportado de SIDERAL (2024-11-22-12:08:38)
Visitas y descargas
The monarchE trial showed that the addition of abemaciclib improves efficacy in patients with high-risk early breast cancer (EBC). We analyzed the long-term outcomes of a population similar to the monarchE trial to put into context the potential benefit of abemaciclib.
Methods
HR-positive/HER2-negative EBC patients eligible for the monarchE study were selected from 3 adjuvant clinical trials and a breast cancer registry. Patients with ≥ 4 positive axillary lymph nodes (N +) or 1–3 N + with tumor size ≥ 5 cm and/or histologic grade 3 and/or Ki67 ≥ 20%, who had undergone surgery with curative intent and had received anthracyclines ± taxanes and endocrine therapy in the neoadjuvant and /or adjuvant setting were included. We performed analysis of Invasive Disease-Free Survival (iDFS), Distant Disease-Free Survival (dDFS) and Overall Survival (OS) at 5 and 10 years, as well as yearly (up to 10) of Invasive Relapse Rate (IRR), Distant Relapse Rate (DRR) and Death Rate (DR).
Results
A total of 1,617 patients were analyzed from the GEICAM-9906 (312), GEICAM-2003–10 (210), and GEICAM-2006–10 (160) trials plus 935 from El Álamo IV. With a median follow-up of 10.1 years, the 5 and 10 years iDFS rates were 75.2% and 57.0%, respectively. The dDFS and OS rates at 5 years were 77.4% and 88.8% and the respective figures at 10 years were 59.7% and 70.9%.
Conclusions
This data points out the need for new therapies for those patients. A longer follow-up of the monarchE study to see the real final benefit with abemaciclib is warranted.
Idioma: Inglés
DOI: 10.1007/s10549-023-07002-1
Año: 2023
Publicado en: BREAST CANCER RESEARCH AND TREATMENT 201, 2 (2023), 151-159
ISSN: 0167-6806
Factor impacto JCR: 3.0 (2023)
Categ. JCR: ONCOLOGY rank: 142 / 322 = 0.441 (2023) - Q2 - T2
Factor impacto CITESCORE: 6.8 - Cancer Research (Q2) - Oncology (Q2)
Factor impacto SCIMAGO: 1.267 - Oncology (Q1) - Cancer Research (Q2)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. Exportado de SIDERAL (2024-11-22-12:08:38)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Medicina
Registro creado el 2023-08-30, última modificación el 2024-11-25